In a highly unusual move, two seasoned sell-side biotech analysts at Cantor Fitzgerald are calling for the Trump administration to replace HHS Secretary Robert F. Kennedy, Jr., following the resignation of one of the U.S. FDA’s top officials, Peter Marks.